Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Schizophrenia

  Free Subscription


Articles published in Neuropsychopharmacology

Retrieve available abstracts of 59 articles:
HTML format
Text format



Single Articles


    March 2019
  1. LEUCHT S, Barabassy A, Laszlovszky I, Szatmari B, et al
    Linking PANSS negative symptom scores with the Clinical Global Impressions Scale: understanding negative symptom scores in schizophrenia.
    Neuropsychopharmacology. 2019 Mar 5. pii: 10.1038/s41386-019-0363.
    PubMed     Text format     Abstract available


  2. BITTER I, Lieberman JA, Gaudoux F, Sokoloff P, et al
    Randomized, double-blind, placebo-controlled study of F17464, a preferential D3 antagonist, in the treatment of acute exacerbation of schizophrenia.
    Neuropsychopharmacology. 2019 Mar 1. pii: 10.1038/s41386-019-0355.
    PubMed     Text format     Abstract available


    February 2019
  3. KRUIPER C, Glenthoj BY, Oranje B
    Effects of clonidine on MMN and P3a amplitude in schizophrenia patients on stable medication.
    Neuropsychopharmacology. 2019 Feb 23. pii: 10.1038/s41386-019-0351.
    PubMed     Text format     Abstract available


  4. MCKINNEY BC, MacDonald ML, Newman JT, Shelton MA, et al
    Density of small dendritic spines and microtubule-associated-protein-2 immunoreactivity in the primary auditory cortex of subjects with schizophrenia.
    Neuropsychopharmacology. 2019 Feb 22. pii: 10.1038/s41386-019-0350.
    PubMed     Text format     Abstract available


  5. MAHMOUDI E, Fitzsimmons C, Geaghan M, Shannon Weickert C, et al
    Circular RNA biogenesis is decreased in postmortem cortical gray matter in schizophrenia and may alter the bioavailability of associated miRNA.
    Neuropsychopharmacology. 2019 Feb 20. pii: 10.1038/s41386-019-0348.
    PubMed     Text format     Abstract available


  6. STJEPAN C, Gregor L, Stephanie T, Christina A, et al
    Reduced auditory evoked gamma-band response and schizophrenia-like clinical symptoms under subanesthetic ketamine.
    Neuropsychopharmacology. 2019 Feb 6. pii: 10.1038/s41386-019-0328.
    PubMed     Text format     Abstract available


    January 2019
  7. HOMAN P, Argyelan M, DeRosse P, Szeszko P, et al
    Structural similarity networks predict clinical outcome in early-phase psychosis.
    Neuropsychopharmacology. 2019 Jan 24. pii: 10.1038/s41386-019-0322.
    PubMed     Text format     Abstract available


  8. DAVIES C, Paloyelis Y, Rutigliano G, Cappucciati M, et al
    Oxytocin modulates hippocampal perfusion in people at clinical high risk for psychosis.
    Neuropsychopharmacology. 2019 Jan 9. pii: 10.1038/s41386-018-0311.
    PubMed     Text format     Abstract available


  9. WYNN JK, Green MF, Hellemann G, Reavis EA, et al
    A dose-finding study of oxytocin using neurophysiological measures of social processing.
    Neuropsychopharmacology. 2019;44:289-294.
    PubMed     Text format     Abstract available


    December 2018
  10. BRUCATO G, Appelbaum PS, Masucci MD, Rolin S, et al
    Prevalence and phenomenology of violent ideation and behavior among 200 young people at clinical high-risk for psychosis: an emerging model of violence and psychotic illness.
    Neuropsychopharmacology. 2018 Dec 27. pii: 10.1038/s41386-018-0304.
    PubMed     Text format     Abstract available


  11. SHAHAB S, Mulsant BH, Levesque ML, Calarco N, et al
    Brain structure, cognition, and brain age in schizophrenia, bipolar disorder, and healthy controls.
    Neuropsychopharmacology. 2018 Dec 20. pii: 10.1038/s41386-018-0298.
    PubMed     Text format     Abstract available


    November 2018
  12. TAKEUCHI H, Siu C, Remington G, Fervaha G, et al
    Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia.
    Neuropsychopharmacology. 2018 Nov 22. pii: 10.1038/s41386-018-0278.
    PubMed     Text format     Abstract available


    October 2018
  13. HOCHBERGER WC, Joshi YB, Thomas ML, Zhang W, et al
    Neurophysiologic measures of target engagement predict response to auditory-based cognitive training in treatment refractory schizophrenia.
    Neuropsychopharmacology. 2018 Oct 30. pii: 10.1038/s41386-018-0256.
    PubMed     Text format     Abstract available


  14. VANOVER KE, Davis RE, Zhou Y, Ye W, et al
    Dopamine D2 receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia.
    Neuropsychopharmacology. 2018 Oct 26. pii: 10.1038/s41386-018-0251.
    PubMed     Text format     Abstract available


  15. SCHWEIGER JI, Bilek E, Schafer A, Braun U, et al
    Effects of BDNF Val(66)Met genotype and schizophrenia familial risk on a neural functional network for cognitive control in humans.
    Neuropsychopharmacology. 2018 Oct 25. pii: 10.1038/s41386-018-0248.
    PubMed     Text format     Abstract available


  16. LEGIND CS, Broberg BV, Mandl RCW, Brouwer R, et al
    Heritability of cerebral glutamate levels and their association with schizophrenia spectrum disorders: a (1)[H]-spectroscopy twin study.
    Neuropsychopharmacology. 2018 Oct 9. pii: 10.1038/s41386-018-0236.
    PubMed     Text format     Abstract available


  17. GONCALVES VF, Cuperfain AB, Kennedy JL
    Sex differences in schizophrenia: estrogen and mitochondria.
    Neuropsychopharmacology. 2018 Oct 7. pii: 10.1038/s41386-018-0228.
    PubMed     Text format    


  18. MODINOS G, Simsek F, Azis M, Bossong M, et al
    Correction: Prefrontal GABA levels, hippocampal resting perfusion and the risk of psychosis.
    Neuropsychopharmacology. 2018 Oct 2. pii: 10.1038/s41386-018-0118.
    PubMed     Text format     Abstract available


    September 2018
  19. SONNENSCHEIN SF, Gill KM, Grace AA
    State-dependent effects of the D2 partial agonist aripiprazole on dopamine neuron activity in the MAM neurodevelopmental model of schizophrenia.
    Neuropsychopharmacology. 2018 Sep 18. pii: 10.1038/s41386-018-0219.
    PubMed     Text format     Abstract available


  20. BOGART LJ, O'Donnell P
    Multiple long-range inputs evoke NMDA currents in prefrontal cortex fast-spiking interneurons.
    Neuropsychopharmacology. 2018;43:2101-2108.
    PubMed     Text format     Abstract available


    August 2018
  21. CHUNG DW, Chung Y, Bazmi HH, Lewis DA, et al
    Altered ErbB4 splicing and cortical parvalbumin interneuron dysfunction in schizophrenia and mood disorders.
    Neuropsychopharmacology. 2018 Aug 2. pii: 10.1038/s41386-018-0169.
    PubMed     Text format     Abstract available


    July 2018
  22. SHAKORY S, Watts JJ, Hafizi S, Da Silva T, et al
    Hippocampal glutamate metabolites and glial activation in clinical high risk and first episode psychosis.
    Neuropsychopharmacology. 2018 Jul 28. pii: 10.1038/s41386-018-0163.
    PubMed     Text format     Abstract available


  23. FAAY MDM, Czobor P, Sommer IEC
    Efficacy of typical and atypical antipsychotic medication on hostility in patients with psychosis-spectrum disorders: a review and meta-analysis.
    Neuropsychopharmacology. 2018 Jul 23. pii: 10.1038/s41386-018-0161.
    PubMed     Text format     Abstract available


  24. RAJAGOPAL L, Huang M, Michael E, Kwon S, et al
    TPA-023 attenuates subchronic phencyclidine-induced declarative and reversal learning deficits via GABAA receptor agonist mechanism: possible therapeutic target for cognitive deficit in schizophrenia.
    Neuropsychopharmacology. 2018 Jul 23. pii: 10.1038/s41386-018-0160.
    PubMed     Text format     Abstract available


    June 2018
  25. ULIANA DL, Resstel LBM, Grace AA
    Fear extinction disruption in a developmental rodent model of schizophrenia correlates with an impairment in basolateral amygdala-medial prefrontal cortex plasticity.
    Neuropsychopharmacology. 2018 Jun 23. pii: 10.1038/s41386-018-0128.
    PubMed     Text format     Abstract available


    May 2018
  26. HOLPER L, Ben-Shachar D, Mann JJ
    Multivariate meta-analyses of mitochondrial complex I and IV in major depressive disorder, bipolar disorder, schizophrenia, Alzheimer disease, and Parkinson disease.
    Neuropsychopharmacology. 2018 May 16. pii: 10.1038/s41386-018-0090.
    PubMed     Text format     Abstract available


  27. NOUR MM, McCutcheon R, Howes OD
    The Relationship Between Dopamine Synthesis Capacity and Release: Implications for Psychosis.
    Neuropsychopharmacology. 2018;43:1195-1196.
    PubMed     Text format    


    April 2018
  28. NEVES GA, Grace AA
    alpha7 Nicotinic receptor-modulating agents reverse the hyperdopaminergic tone in the MAM model of schizophrenia.
    Neuropsychopharmacology. 2018 Apr 19. pii: 10.1038/s41386-018-0066.
    PubMed     Text format     Abstract available


  29. CHIAPPELLI J, Rowland LM, Notarangelo FM, Wijtenburg SA, et al
    Salivary kynurenic acid response to psychological stress: inverse relationship to cortical glutamate in schizophrenia.
    Neuropsychopharmacology. 2018 Apr 18. pii: 10.1038/s41386-018-0072.
    PubMed     Text format     Abstract available


  30. HAFIZI S, Da Silva T, Meyer JH, Kiang M, et al
    Interaction between TSPO-a neuroimmune marker-and redox status in clinical high risk for psychosis: a PET-MRS study.
    Neuropsychopharmacology. 2018 Apr 13. pii: 10.1038/s41386-018-0061.
    PubMed     Text format     Abstract available


  31. AVRAM M, Brandl F, Bauml J, Sorg C, et al
    Cortico-thalamic hypo- and hyperconnectivity extend consistently to basal ganglia in schizophrenia.
    Neuropsychopharmacology. 2018 Apr 12. pii: 10.1038/s41386-018-0059.
    PubMed     Text format     Abstract available


  32. ERMAKOVA AO, Knolle F, Justicia A, Bullmore ET, et al
    Abnormal reward prediction-error signalling in antipsychotic naive individuals with first-episode psychosis or clinical risk for psychosis.
    Neuropsychopharmacology. 2018 Apr 5. pii: 10.1038/s41386-018-0056.
    PubMed     Text format     Abstract available


  33. KESHAVAN MS
    Larry J Seidman.
    Neuropsychopharmacology. 2018;43:1189-1190.
    PubMed     Text format    


    March 2018
  34. DOGAN AE, Yuksel C, Du F, Chouinard VA, et al
    Brain lactate and pH in schizophrenia and bipolar disorder: a systematic review of findings from magnetic resonance studies.
    Neuropsychopharmacology. 2018 Mar 14. pii: 10.1038/s41386-018-0041.
    PubMed     Text format     Abstract available


    February 2018
  35. CHIAPPELLI J, Notarangelo FM, Pocivavsek A, Thomas MAR, et al
    Influence of plasma cytokines on kynurenine and kynurenic acid in schizophrenia.
    Neuropsychopharmacology. 2018 Feb 27. pii: 10.1038/s41386-018-0038.
    PubMed     Text format     Abstract available


  36. O'DONOVAN SM, Sullivan C, Koene R, Devine E, et al
    Cell-subtype-specific changes in adenosine pathways in schizophrenia.
    Neuropsychopharmacology. 2018 Feb 26. pii: 10.1038/s41386-018-0028.
    PubMed     Text format     Abstract available


  37. BARNETT I, Torous J, Staples P, Sandoval L, et al
    Relapse prediction in schizophrenia through digital phenotyping: a pilot study.
    Neuropsychopharmacology. 2018 Feb 22. pii: 10.1038/s41386-018-0030.
    PubMed     Text format     Abstract available


  38. BERNSTEIN HG, Dobrowolny H, Keilhoff G, Bogerts B, et al
    Reduced Density of DISC1 Expressing Astrocytes in the Dentate Gyrus but not in the Subventricular Zone in Schizophrenia.
    Neuropsychopharmacology. 2018;43:457-458.
    PubMed     Text format    


  39. ALLSWEDE DM, Zheutlin AB, Chung Y, Anderson K, et al
    Complement Gene Expression Correlates with Superior Frontal Cortical Thickness in Humans.
    Neuropsychopharmacology. 2018;43:525-533.
    PubMed     Text format     Abstract available


    January 2018
  40. MODINOS G, Simsek F, Azis M, Bossong M, et al
    Prefrontal GABA levels, hippocampal resting perfusion and the risk of psychosis.
    Neuropsychopharmacology. 2018 Jan 30. pii: 10.1038/s41386-017-0004.
    PubMed     Text format     Abstract available


  41. YOUNG JW, Light GA
    Cross-Species Neurophysiological Biomarkers of Attentional Dysfunction in Schizophrenia: Bridging the Translational Gap.
    Neuropsychopharmacology. 2018;43:230-231.
    PubMed     Text format    


    December 2017
  42. DOYLE GA, Berrettini WH
    Failure to Replicate an Association of a LINE-1 Element in ERI1 Exoribonuclease Family Member 3 (ERI3) with Schizophrenia.
    Neuropsychopharmacology. 2017;42:2471.
    PubMed     Text format    


    November 2017
  43. PERKINS KA, Chengappa KR, Karelitz JL, Boldry MC, et al
    Initial Cross-Over Test of a Positive Allosteric Modulator of Alpha-7 Nicotinic Receptors to Aid Cessation in Smokers with or Without Schizophrenia.
    Neuropsychopharmacology. 2017 Nov 29. pii: npp2017292. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


  44. SWERDLOW NR, Bhakta SG, Talledo JA, Franz DM, et al
    Effects of Amphetamine on Sensorimotor Gating and Neurocognition in Antipsychotic-Medicated Schizophrenia Patients.
    Neuropsychopharmacology. 2017 Nov 20. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


  45. NAGELS A, Cabanis M, Oppel A, Kirner-Veselinovic A, et al
    S-Ketamine-Induced NMDA Receptor Blockade During Natural Speech Production and its Implications for Formal Thought Disorder in Schizophrenia: A Pharmaco-fMRI Study.
    Neuropsychopharmacology. 2017 Nov 6. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


  46. STEFANIK L, Erdman L, Ameis SH, Foussias G, et al
    Brain-Behavior Participant Similarity Networks Among Youth and Emerging Adults with Schizophrenia Spectrum, Autism Spectrum, or Bipolar Disorder and Matched Controls.
    Neuropsychopharmacology. 2017 Nov 6. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


  47. GIRGIS RR, Ciarleglio A, Choo T, Haynes G, et al
    A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Tocilizumab, an Interleukin-6 Receptor Antibody, for Residual Symptoms in Schizophrenia.
    Neuropsychopharmacology. 2017 Nov 1. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


    September 2017
  48. SMUCNY J, Lesh TA, Newton K, Niendam T, et al
    Levels of Cognitive Control: A Functional Magnetic Resonance Imaging-Based Test of an RDoC Domain Across Bipolar Disorder and Schizophrenia.
    Neuropsychopharmacology. 2017 Sep 26. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


  49. RAMSAY IS, Fryer S, Boos A, Roach BJ, et al
    Response to Targeted Cognitive Training Correlates with Change in Thalamic Volume in a Randomized Trial for Early Schizophrenia.
    Neuropsychopharmacology. 2017 Sep 12. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


    August 2017
  50. KEM WR, Olincy A, Johnson L, Harris J, et al
    Pharmacokinetic Limitations on Effects of an Alpha7 Nicotinic Receptor Agonist in Schizophrenia: Randomized Trial with an Extended Release Formulation.
    Neuropsychopharmacology. 2017 Aug 21. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


  51. O'DONNELL P
    Microglia Activation in Subjects at Risk for Psychosis, Fact or Fiction?
    Neuropsychopharmacology. 2017 Aug 18. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


  52. LEE M, Balla A, Sershen H, Sehatpour P, et al
    Rodent Mismatch Negativity (MMN)/Theta Neuro-Oscillatory Response as a Translational Neurophysiological Biomarker for N-Methyl-D-Aspartate Receptor-Based New Treatment Development in Schizophrenia.
    Neuropsychopharmacology. 2017 Aug 17. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


    July 2017
  53. BRUCATO G, Appelbaum PS, Lieberman JA, Wall MM, et al
    A Longitudinal Study of Violent Behavior in a Psychosis-Risk Cohort.
    Neuropsychopharmacology. 2017 Jul 26. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


    June 2017
  54. COSGROVE D, Mothersill O, Kendall K, Konte B, et al
    Cognitive Characterization of Schizophrenia Risk Variants Involved in Synaptic Transmission: Evidence of CACNA1C's Role in Working Memory.
    Neuropsychopharmacology. 2017 Jun 13. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


  55. HAFIZI S, Da Silva T, Gerritsen C, Kiang M, et al
    Imaging Microglial Activation in Individuals at Clinical High Risk for Psychosis: An In-Vivo PET Study with [18F]FEPPA.
    Neuropsychopharmacology. 2017 Jun 12. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


  56. DOYLE GA, Crist RC, Karatas ET, Hammond MJ, et al
    Analysis of LINE-1 Elements in DNA from Postmortem Brains of Individuals with Schizophrenia.
    Neuropsychopharmacology. 2017 Jun 6. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


    April 2017
  57. RABIN RA, Barr MS, Goodman MS, Herman Y, et al
    Effects of Extended Cannabis Abstinence on Cognitive Outcomes in Cannabis Dependent Patients with Schizophrenia versus Non-Psychiatric Controls.
    Neuropsychopharmacology. 2017 Apr 26. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


  58. LIGHT GA, Zhang W, Joshi YB, Bhakta S, et al
    Single-Dose Memantine Improves Cortical Oscillatory Response Dynamics in Patients with Schizophrenia.
    Neuropsychopharmacology. 2017 Apr 20. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


  59. EISENBERG DP, Yankowitz L, Ianni AM, Rubinstein DY, et al
    Presynaptic Dopamine Synthesis Capacity in Schizophrenia and Striatal Blood Flow Change During Antipsychotic Treatment and Medication-Free Conditions.
    Neuropsychopharmacology. 2017 Apr 7. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Schizophrenia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: